Allegiant Private Advisors’s Merck MRK Stock Holding History

Allegiant Private Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$673K	Buy	8,650 +443	+5%	+$33K	0.11%	93
2021 Q1	$604K	Sell	8,207 -102	-1%	-$7.52K	0.11%	91
2020 Q4	$649K	Buy	+8,309	New	+$635K	0.13%	83

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Allegiant Private Advisors's MRK Position: Q2 2021 in Review

Allegiant Private Advisors increased its Merck (MRK) stake by 5.4% in Q2 2021, buying an estimated $33K and bringing the position to 8,650 shares worth $673K. The position accounts for 0.11% of the portfolio, ranked #93.

Allegiant Private Advisors first reported a position in MRK in Q4 2020 and has held it in 3 quarters since. 2,673 funds tracked by Wall St. Rank hold MRK as of Q2 2021.

Allegiant Private Advisors held 8,650 shares of Merck worth $673K as of Q2 2021.
Allegiant Private Advisors bought 443 Merck shares in Q2 2021, an estimated $33K.
Merck made up 0.11% of Allegiant Private Advisors's portfolio in Q2 2021, its #93 holding.
Allegiant Private Advisors first reported a position in Merck in Q4 2020 and has held it in 3 quarters since.
2,673 funds tracked by Wall St. Rank held Merck as of Q2 2021.

Based on Allegiant Private Advisors's 13F filing for Q2 2021, filed 7 Jul 2021.